← Apimeds Pharmaceuticals US, Inc. (APUS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Apimeds Pharmaceuticals US, Inc. (APUS)
Pharmaceutical Preparations · market cap $7M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Apimeds Pharmaceuticals US, Inc. (APUS) is a micro-cap pharmaceutical company with a market capitalization of approximately $16M and a share price near $0.66. Its lead asset is a histamine-based therapy in Phase 3 development for osteoarthritis of the knee, with a secondary pipeline asset being honeybee venom-derived Apitox (USA) / Apitoxin (Korea) in Phase 2 for the same indication. Financial details, cash runway, and analyst coverage are not publicly available in the provided data.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| histamine | Phase 3 | Osteoarthritis of the Knee |
| honeybee venom (Apitoxin (Korea) Apitox (USA)) | Phase 2 | Osteoarthritis of the Knee |
Price & technical context
3-month
-34.5%
6-month
-74.3%
12-month
-74.2%
52-wk range
$1.60–$38.95
vs 50-day MA
+21.4%
vs 200-day MA
-59.5%
Realized vol
189.8%
Max drawdown
-95.9%
Daily closes through 2026-10-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APUS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.